“There is no reason other than a Prozac reaction,” said Dr. Peter Breggin, a New York state-based psychiatrist and author of the book, Talking Back to Prozac. “(The killing) is a mystery without that.”
Nine days after starting therapy with the drug, the teen attempted suicide via an overdose of his grandfather’s pills. His parents reported the incident to doctors, who increased the Prozac dosage for the teen.
The discovery that many people with life problems or occasional bad moods would willingly dose themselves with antidepressants sailed pharma through the 2000s. A good chunk of pharma’s $4.5 billion direct-to-consumer advertising has been devoted to convincing people they don’t have problems with their job, the economy and their family, they have depression. Especially because depression can’t be diagnosed from a blood test.
Unfortunately, three things dried up the depression gravy train for pharma. Blockbusters went off patent and generics took off, antidepressants were linked with gory and unpredictable violence, especially in young users and…they didn’t even work, according to medical article
(NaturalNews) “If mentally incapacitated troops are being drugged with dangerous, mind-altering drugs and deployed to battle against their will, how can we say that we have a volunteer army?” asked Alliance for Human Research Protection, the national network dedicated to advancing responsible and ethical medical research practices.
This is just one of the many criticisms being levied against the U.S. military in light of its liberal use of prescription medication, which is now being linked to rising suicide rates among soldiers.
It seems McGorry has a growing army of critics, pity the Aussie government can’t see through his crystal ball gazing as many others can – it’s akin to taking a losing lottery ticket up to a paypoint and…well, being paid the jackpot prize.
In another effort to shed light on untoward relationships, the FDA has just issued a draft guidance on financial conflicts of interest for clinical investigators and the drugmakers that enlist their assistance. The document is designed to revise a 10-year set of rules and address an issue that has grown increasingly contentious in recent years.
SHARE YOUR STORY/COMMENT: